For in vitro diagnostic (IVD) use with the Lumipulse G system for detection and quantitative measurement of SARS-CoV-2 nucleocapsid protein antigen in human nasopharyngeal swab or saliva. As a diagnostic tool for the confirmation of a SARS-CoV-2 infection.
The assay utilises proven CLEIA (chemiluminescent enzyme immunoassay) technology with results that are available in up to 35 minutes. Please note that Lumipulse G assay need to be performed on either our LUMIPULSE G600II or LUMIPULSE G1200 in a clinical laboratory.
Lumipulse® G SARS-CoV-2 Ag Immunoreaction Cartridges
Product number 260340 3 x 14 Tests
Lumipulse® G SARS-CoV-2 Ag Calibrators
Product number 231869 4 x 4 Concentrations
The 2019 novel coronavirus infection disease (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1,2 In December 2019, the Health Commission of the City of Wuhan, Hubei Province, China, reported multiple pneumonia patients with unknown cause. On January 7th 2020, the World Health Organization (WHO) announced that the National Health Commission of China identified a new type of coronavirus, SARS-CoV-2.3 The WHO declared a COVID-19 pandemic on March 11th 2020 due to the worldwide spread of novel coronavirus infection.4